argenx vs Grifols (ARGX.BR vs GRF)

argenx (ARGX.BR) vs Grifols (GRF) in plain English: P/E, growth, margins, debt and dividend side by side, key differences and which fits each investor profile.

argenx (ARGX.BR) and Grifols (GRF) compete in healthcare and pharma. Here are argenx and Grifols side by side with their real figures as of November 4, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy argenx or Grifols.

argenx vs Grifols: the figures

argenx and Grifols figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026; N/A means that argenx or Grifols figure is not available, and we never estimate it.

3 key differences between argenx and Grifols

1. Growth: argenx grew sales +52.1% year on year in its latest quarter, against +9.4% for Grifols.
2. Debt: Grifols owes 5.0x its annual operating profit (EBITDA), while argenx holds more cash than debt.
3. Valuation: argenx trades at 32.8x its annual earnings and Grifols at 15.8x; the market pays more for each dollar of argenx profit, usually because it expects more growth.

argenx or Grifols: which fits your profile

• If you want growth: argenx is growing faster today, so it fits better with investors who put business growth first, usually accepting a higher P/E and a bumpier ride.
• If you want income (dividends): Grifols pays the higher dividend relative to its price.
• If you prefer caution: argenx has less debt relative to its profit, which usually gives more room in a bad year.
• If price is what matters most to you: Grifols trades on the lower P/E; check first whether that is an opportunity or a sign of a business that grows less.

Neither argenx nor Grifols wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.

How argenx and Grifols make money

argenx (ARGX.BR)

argenx is a biotech that earns its money from Vyvgart, its antibody-based treatment for autoimmune diseases such as myasthenia gravis and CIDP, sold in IV and under-the-skin forms. Nearly all sales come from this product, mostly in the US, followed by Japan and Europe, and it reinvests in research for new uses. Full argenx analysis.

Grifols (GRF)

Grifols collects plasma from donors at its network of centers, mostly in the US, and turns it into medicines. Its Biopharma division, the largest, sells immunoglobulins, albumin and other plasma proteins to hospitals; Diagnostic provides blood-screening tests for blood banks and labs; and Bio Supplies sells biological materials. Full Grifols analysis.

Frequently asked questions: argenx vs Grifols

Is argenx or Grifols the better stock?

Choosing between argenx and Grifols depends on what you are looking for. argenx is growing faster right now, and Grifols trades on the lower P/E. Fintols does not tell you whether to buy argenx or Grifols: it shows you the differences so you can decide.

Which pays a higher dividend, argenx or Grifols?

As of November 4, 2026, Grifols yields 0.73% and argenx pays none. Also check how much of their profit argenx and Grifols pay out: if it is more than they earn, it cannot last.

Which is more expensive, argenx or Grifols?

On P/E, argenx (32.8x) is more expensive than Grifols (15.8x) as of November 4, 2026. A higher P/E can be justified if earnings grow faster, so compare it with each company's growth in the table.

Can I own both argenx and Grifols?

Yes. Many people spread their money across several companies, such as argenx and Grifols, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying argenx or Grifols.

More comparisons with argenx or Grifols

• argenx vs Bayer
• argenx vs Laboratorios Rovi
• argenx vs Sanofi
• Grifols vs Laboratorios Rovi

More companies like argenx and Grifols: healthcare and pharma stocks. Educational content about argenx and Grifols, not investment advice.